Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

0.9095

+0.0205

(+2.31%)

As of 03:29PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.8890
Open	0.8800
Bid	0.9000 x 1200
Ask	0.9200 x 1000
Day's Range	0.8712 - 0.9254
52 Week Range	0.8000 - 3.8400
Volume	116,554
Avg. Volume	100,719

Market Cap	40.863M
Beta (5Y Monthly)	1.43
PE Ratio (TTM)	N/A
EPS (TTM)	-0.4640
Earnings Date	Feb 07, 2022 - Feb 11, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	5.02

All

GlobeNewswire
Acasti Pharma Reports First Quarter 2023 Operational Results
Company to Host Conference Call Today at 1:00pm ETLAVAL, Québec, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced financial and operational results for the first quarter ended June 30, 2022. Recent Highlights The Company is preparing the GTX-104 PK bridging study results for submission to the U.S
- HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
  GlobeNewswire
- NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
  GlobeNewswire
GlobeNewswire
Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022
Call to be held on Thursday, August 11th at 1:00 PM Eastern Time LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, August 11, 2022, to discuss the Company’s corporate progress and other developments, as well as financial results for first quarter 2023 ended June 30, 2022. The conference call will be available via telephone by diali
GlobeNewswire
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug bupivacaine in 48 healthy subjects. Feedback from FDA was obtained on the study protocol, and the non-objection letter was received on July 12th from Health Canada. The First-Subject, First-Dose was a